Samsung Peptide AG, a direct subsidiary, announced a formal public tender offer for PolyPeptide shares.
Samsung Biologics has released the prospectus for a public tender offer, with its direct subsidiary Samsung Peptide AG acting as the formal offeror. The prospectus follows a pre-announcement made on July 20, 2026. The company’s largest individual shareholder has pledged to tender all of its PolyPeptide shares into the offer, and the main offer period is expected to run for several weeks, though exact dates have not yet been disclosed. This move signals a strategic restructuring of Samsung’s peptide manufacturing assets and may affect future collaborations and supply arrangements within the peptide research community.
Source: PR Newswire
Written from a press release issued by PR Newswire. Read the original.
For research use only. All products supplied by PepXtide are intended strictly for in-vitro laboratory research. They are not intended for human or veterinary use, consumption, or therapeutic application, and are not sold as drugs, food, or dietary supplements. These statements have not been evaluated by the FDA. Customers are responsible for compliance with applicable regulations in their jurisdiction.